Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Stemcentrx

Biotech & Life Sciences · South San Francisco, United States · Founded 2008 Decacorn

Develops innovative therapies for cancer

Valuation
$10–50B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value

Investors

7 investors on Stemcentrx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 7 investors entered at this stage

Global footprint

Where Stemcentrx has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Patent intelligence

$51M patent portfolio · 20 active families

Estimated portfolio value
$51M
0.50% of valuation · 15.4× smaller than top peer BioNTech ($780M)
20 active patent families
Where Stemcentrx innovates Molecular biologyAntiendomysial antibodiesAntibody-drug conjugatePharmaceutical drugImmunology

Where Stemcentrx concentrates vs peers

Each axis is a top-10 topic across Stemcentrx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Stemcentrx

An AI-synthesized read of the highest-engagement posts about Stemcentrx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Stemcentrx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.